Caption: CEL-SCI Corporation (NYSE MKT: CVM) today announced that it has signed a co-development and profit sharing agreement with Ergomed Clinical Research Ltd. for CEL-SCI’s investigational immunotherapy drug Multikine (“Leucocyte Interleukin In
Credit: CEL-SCI Corporation